COMPANY
Location: Lansing, MI · source · Oct 12, 2026
Profile checked Oct 10, 2026
Keywords: Myocardial Ischemia Coronary Disease Coronary Artery Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases
Timeline
- Raise Private equity round: $30M (total, as published), announced Apr 21, 2026. Source: company's own press page. source ↗
- Partnership Partnership / licensing announced Jun 20, 2025. Source: company's own press page. source ↗
- Trial start —: Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP) source ↗
Funding
Raised: $30.0M. Last 2 years.
- Private equity round: $30M (total, as published), announced Apr 21, 2026. Source: company's own press page. source ↗
- Partnership / licensing announced Jun 20, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT04343209 | Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP) | Not listed | Completed | Sep 14, 2020 | Aug 16, 2024 (actual) |